Entry here is still stupid cheap. Another excerpt from the SA article -- "Here's an overview of peer Phase III small cap biotechs targeting specific cancer types with respectively their market valuations: Oncothyreon (NASDAQ:ONTY): $150 million valuation Endocyte (NASDAQ:ECYT): $280 million valuation Galena Biopharma (NASDAQ:GALE): $280 valuation Mind you that most Phase III biotech stocks have much higher valuations (some in the billions), but I searched in the lowest bracket of valuations, and for companies targeting specific cancer types, so their addressable markets are more or less of similar size. A remarkable thing is that some companies failed their Phase III trials so far (OncoGenex for example), but still are valued at multiples of Bioniche. Other have weak financials, and are also valued much higher. So even in the lowest bracket of Phase III biotechs, valuations turn out to be 3X to 10X higher than Bioniche's, emphasizing clearly what a phenomenal buying opportunity Bioniche is."